-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, T0pbJRJoMSIfG2BgUv4gsvXjD35Y0eEhhdQaj+46Fh+lyHMtJXp5vY70uaOR+VGf t4E8eSf4t7SD2+NRBqwuXQ== 0001235802-09-000120.txt : 20091015 0001235802-09-000120.hdr.sgml : 20091015 20091015192835 ACCESSION NUMBER: 0001235802-09-000120 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20091014 FILED AS OF DATE: 20091015 DATE AS OF CHANGE: 20091015 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: SHERWIN STEPHEN A CENTRAL INDEX KEY: 0001079462 STATE OF INCORPORATION: DE FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-31812 FILM NUMBER: 091122240 MAIL ADDRESS: STREET 1: C/O CELL GENESYS, INC. STREET 2: 500 FORBES BLVD. CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BIOSANTE PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001023024 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 582301143 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 111 BARCLAY BLVD STE 280 CITY: LINCOLNSHIRE STATE: IL ZIP: 60069 BUSINESS PHONE: 8474780500 MAIL ADDRESS: STREET 1: 111 BARCLAY BLVD STE 280 CITY: LINCOLNSHIRE STATE: IL ZIP: 60069 FORMER COMPANY: FORMER CONFORMED NAME: BEN ABRAHAM TECHNOLOGIES INC DATE OF NAME CHANGE: 19991027 4 1 primary_doc.xml PRIMARY DOCUMENT X0303 4 2009-10-14 0 0001023024 BIOSANTE PHARMACEUTICALS INC bpax 0001079462 SHERWIN STEPHEN A C/O BIOSANTE PHARMACEUTICALS, INC. 111 BARCLAY BOULEVARD LINCOLNSHIRE IL 60069 1 0 0 0 Common Stock 2009-10-14 4 A 0 86760 A 86760 D Stock Option (right to buy) 10.07 2009-10-14 4 A 0 10101 A 2018-02-06 Common Stock 10101 10101 D Stock Option (right to buy) 10.07 2009-10-14 4 A 0 58448 A 2018-02-06 Common Stock 58448 58448 D Stock Option (right to buy) 16.8 2009-10-14 4 A 0 5074 A 2017-02-07 Common Stock 5074 5074 D Stock Option (right to buy) 16.8 2009-10-14 4 A 0 13205 A 2017-02-07 Common Stock 13205 13205 D Stock Option (right to buy) 33.21 2009-10-14 4 A 0 3406 A 2016-02-07 Common Stock 3406 3406 D Stock Option (right to buy) 33.21 2009-10-14 4 A 0 7561 A 2016-02-07 Common Stock 7561 7561 D Stock Option (right to buy) 36.82 2009-10-14 4 A 0 18325 A 2015-02-03 Common Stock 18325 18325 D Stock Option (right to buy) 36.82 2009-10-14 4 A 0 2239 A 2015-02-03 Common Stock 2239 2239 D Stock Option (right to buy) 1.82 2009-10-14 4 A 0 15000 0 A 2019-10-13 Commom Stock 15000 15000 D Received in exchange for 474,621 shares of Cell Genesys, Inc. ("Cell Genesys") common stock in connection with the merger of Cell Genesys with and into BioSante (the "Merger"). Each share of the reporting person's Cell Genesys shares was exchanged for 0.1828 of a share of BioSante common stock in connection with the Merger. Options granted on February 6, 2008. Vesting occurs over a period of four years in a series of forty-eight (48) successive, equal monthly installments beginning on the grant date. Received in the Merger in exchange for an employee stock option to acquire 55,260 shares of Cell Genesys common stock for an exercise price of $1.84 per share. Received in the Merger in exchange for an employee stock option to acquire 319,740 shares of Cell Genesys common stock for an exercise price of $1.84 per share. Options granted on February 7, 2007. Vesting occurs over a period of four years in a series of forty-eight (48) successive, equal monthly installments beginning on the grant date. Received in the Merger in exchange for an employee stock option to acquire 27,761 shares of Cell Genesys common stock for an exercise price of $3.07 per share. Received in the Merger in exchange for an employee stock option to acquire 72,239 shares of Cell Genesys common stock for an exercise price of $3.07 per share. Options granted on February 7, 2006. Vesting occurs over a period of four years in a series of forty-eight (48) successive, equal monthly installments beginning on the grant date. Received in the Merger in exchange for an employee stock option to acquire 18,633 shares of Cell Genesys common stock for an exercise price of $6.07 per share. Received in the Merger in exchange for an employee stock option to acquire 41,367 shares of Cell Genesys common stock for an exercise price of $6.07 per share. Options granted on February 3, 2005. Vesting occurs over a period of four years in a series of forty-eight (48) successive, equal monthly installments beginning on the grant date. Received in the Merger in exchange for an employee stock option to acquire 100,248 shares of Cell Genesys common stock for an exercise price of $6.73 per share. Received in the Merger in exchange for an employee stock option to acquire 12,252 shares of Cell Genesys common stock for an exercise price of $6.73 per share. Option granted on October 14, 2009. Vesting occurs in four equal yearly installments, with the first installment becoming exercisable on the one-year anniversary of the grant date. /s/ Phillip B. Donenberg, attorney-in-fact 2009-10-14 -----END PRIVACY-ENHANCED MESSAGE-----